All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
How does linvoseltamab differ from other bispecific antibodies?
Featured
Bookmark this article
The Multiple Myeloma Hub was pleased to speak to Naresh Bumma, The Ohio State University, Columbus, US. We asked, How does linvoseltamab differ from other bispecific antibodies?
How does linvoseltamab differ from other bispecific antibodies?
In this video interview, Naresh Bumma opens by discussing the latest approvals and developments in bispecific antibodies for the treatment of multiple myeloma. He goes on to present key efficacy and safety data from LINKER-MM1 trial (NCT03761108), highlighting the outcomes observed with linvoseltamab compared with data of alternative bispecific antibodies.
Bumma notes the similarity in response rates across the same drug class but highlights infection, neurotoxicity, ICANS and CRS rates as differentiators favoring linvoseltamab over existing bispecific antibodies.
Related articles
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox